Rifaximin, probiotic or L-ornithine L-aspartate plus lactulose vs lactulose alone for overt hepatic encephalopathy

Phase 4, randomised trial of lactulose, rifaximin and l-ornithine l-aspartate in hepatic encephalopathy (HE) and chronic liver disease (CLD) (4 arms), sponsored by The Islamia University of Bahawalpur. Primary endpoint: Reversal in grades of hepatic encephalopathy. Planned start Sep 2023; status: not yet recruiting.